dipyridamole has been researched along with B16 Melanoma in 6 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The cytotoxicity of adriamycin (ADM) combined with hyperthermia (Hyp) and/or dipyridamole (DP) was investigated using B16 melanoma cells in vitro and in vivo." | 3.68 | Adriamycin combined with hyperthermia and dipyridamole is cytotoxic both in vitro and in vivo. ( Emi, Y; Kohnoe, S; Maehara, Y; Sakaguchi, Y; Sugimachi, K, 1992) |
| "Growth of B16 melanoma that had been subcutaneously implanted into the feet of C57 BL mice was inhibited by treatment with the combinations of 5-FU and HYP, of 5-FU and DP, and of 5-FU, HYP and DP as compared with the administration of 5-FU alone." | 1.28 | 5-Fluorouracil's cytotoxicity is enhanced both in vitro and in vivo by concomitant treatment with hyperthermia and dipyridamole. ( Kusumoto, H; Maehara, Y; Masuda, H; Sakaguchi, Y; Sugimachi, K; Takahashi, I; Yoshida, M, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Damle, B | 1 |
| Desai, P | 1 |
| Damle, BD | 2 |
| Sridhar, R | 2 |
| Desai, PB | 2 |
| Duan, J | 1 |
| Juranić, Z | 1 |
| Radulović, S | 1 |
| Joksimović, J | 1 |
| Juranić, I | 1 |
| Sakaguchi, Y | 2 |
| Maehara, Y | 2 |
| Emi, Y | 1 |
| Kohnoe, S | 1 |
| Sugimachi, K | 2 |
| Takahashi, I | 1 |
| Yoshida, M | 1 |
| Kusumoto, H | 1 |
| Masuda, H | 1 |
6 other studies available for dipyridamole and B16 Melanoma
| Article | Year |
|---|---|
Dipyridamole reverses the resistance to topoisomerase II inhibitors but not to antimicrotubule agents in multidrug-resistant melanoma cells.
Topics: Animals; Antineoplastic Agents; Cell Nucleus; Cell Survival; Dipyridamole; DNA Damage; Drug Interact | 1994 |
Dipyridamole modulates multidrug resistance and intracellular as well as nuclear levels of doxorubicin in B16 melanoma cells.
Topics: Animals; Cell Nucleus; Cell Survival; Dipyridamole; Dose-Response Relationship, Drug; Doxorubicin; D | 1994 |
Reversal of doxorubicin resistance in multidrug resistant melanoma cells in vitro and in vivo by dipyridamole.
Topics: Animals; Antibiotics, Antineoplastic; Cells, Cultured; Dipyridamole; Dose-Response Relationship, Dru | 1997 |
The mechanism of 8-Cl-cAMP action.
Topics: 1-Methyl-3-isobutylxanthine; 8-Bromo Cyclic Adenosine Monophosphate; Animals; Antineoplastic Agents; | 1998 |
Adriamycin combined with hyperthermia and dipyridamole is cytotoxic both in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Combined Modality Therapy; D | 1992 |
5-Fluorouracil's cytotoxicity is enhanced both in vitro and in vivo by concomitant treatment with hyperthermia and dipyridamole.
Topics: Animals; Combined Modality Therapy; Dipyridamole; Drug Screening Assays, Antitumor; Drug Synergism; | 1992 |